聯康生物科技集團(00690.HK):硫酸艾沙康唑膠囊上市申請已正式獲國家藥監局受理
格隆匯7月18日丨聯康生物科技集團(00690.HK)發佈公吿,集團遞交的硫酸艾沙康唑膠囊的上市申請已正式獲中國國家藥品監督管理局(“NMPA”)受理,受理號為“CYHS2502599”。這是集團在抗真菌治療領域取得的重要里程碑,硫酸艾沙康唑膠囊預計2026年下半年獲批上市。為廣大侵襲性真菌感染(如侵襲性麴黴病和侵襲性毛黴病)患者提供更有效、更安全的高質量治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.